ENTRY       D11160                      Drug
NAME        Caplacizumab (USAN/INN);
            Caplacizumab (genetical recombination) (JAN);
            Caplacizumab-yhdp;
            Cablivi (TN)
PRODUCT     CABLIVI (Genzyme Corporation)
FORMULA     C1213H1891N357O380S10
EXACT_MASS  27858.6828
MOL_WEIGHT  27875.8075
SEQUENCE    EVQLVESGGG LVQPGGSLRL SCAASGRTFS YNPMGWFRQA PGKGRELVAA ISRTGGSTYY
            PDSVEGRFTI SRDNAKRMVY LQMNSLRAED TAVYYCAAAG VRAEDGRVRT LPSEYTFWGQ
            GTQVTVSSAA AEVQLVESGG GLVQPGGSLR LSCAASGRTF SYNPMGWFRQ APGKGRELVA
            AISRTGGSTY YPDSVEGRFT ISRDNAKRMV YLQMNSLRAE DTAVYYCAAA GVRAEDGRVR
            TLPSEYTFWG QGTQVTVSS
            (Disulfide bridge: 22-96, 153-227)
  TYPE      Peptide
CLASS       Blood modifier agent
             DG01950  Antithrombotic agent
              DG01712  Antiplatelet agent
REMARK      Therapeutic category: 3399
            ATC code: B01AX07
            Product: D11160<JP/US>
EFFICACY    Platelet aggregation inhibitor, Anti-vWF antibody
  DISEASE   Acquired thrombotic thrombocytopenic purpura [DS:H00225]
  TYPE      Monoclonal antibody
COMMENT     Treatment of thrombotic thrombocytopenic purpura, thrombosis
TARGET      VWF [HSA:7450] [KO:K03900]
  PATHWAY   hsa04610(7450)  Complement and coagulation cascades
            hsa04611(7450)  Platelet activation
INTERACTION  
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             B BLOOD AND BLOOD FORMING ORGANS
              B01 ANTITHROMBOTIC AGENTS
               B01A ANTITHROMBOTIC AGENTS
                B01AX Other antithrombotic agents
                 B01AX07 Caplacizumab
                  D11160  Caplacizumab (USAN/INN) &lt;JP/US&gt;
            USP drug classification [BR:br08302]
             Blood Products and Modifiers
              Platelet Modifying Agents
               Platelet Modifying Agents, Other
                Caplacizumab
                 D11160  Caplacizumab (USAN/INN)
            Therapeutic category of drugs in Japan [BR:br08301]
             3  Agents affecting metabolism
              33  Blood and body fluid agents
               339  Miscellaneous
                3399  Others
                 D11160  Caplacizumab (USAN/INN); Caplacizumab (genetical recombination) (JAN)
            Drug groups [BR:br08330]
             Blood modifier agent
              DG01950  Antithrombotic agent
               DG01712  Antiplatelet agent
                D11160  Caplacizumab
            Target-based classification of drugs [BR:br08310]
             Not elsewhere classified
              Organismal systems
               Complement and coagulation
                VWF
                 D11160  Caplacizumab (USAN/INN) &lt;JP/US&gt;
            New drug approvals in the USA [br08319.html]
             New molecular entities and new therapeutic biological products
              D11160
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D11160
            New drug approvals in Japan [br08318.html]
             Drugs with new active ingredients
              D11160
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D11160
DBLINKS     CAS: 915810-67-2
            PubChem: 376219084
///
